AC Immune Ltd
$ 3.07
-2.23%
16 Apr - close price
- Market Cap 312,445,000 USD
- Current Price $ 3.07
- High / Low $ 3.15 / 2.91
- Stock P/E N/A
- Book Value 0.56
- EPS -0.90
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.90 %
- 52 Week High 4.00
- 52 Week Low 1.45
About
AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company is headquartered in Lausanne, Switzerland.
Analyst Target Price
$9.12
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-12 | 2025-11-04 | 2025-08-05 | 2025-05-12 | 2025-03-12 | 2024-11-01 | 2024-08-06 | 2024-05-13 | 2024-03-14 | 2023-11-03 | 2023-08-04 | 2023-04-28 |
| Reported EPS | -0.1401 | -0.16 | -0.21 | -0.19 | -0.16 | 0.06 | -0.23 | -0.18 | -0.05 | -0.18 | -0.2 | -0.21 |
| Estimated EPS | -0.1566 | -0.19 | -0.1742 | -0.207 | -0.1903 | -0.23 | 0.27 | -0.14 | -0.11 | 0.03 | -0.19 | -0.23 |
| Surprise | 0.0165 | 0.03 | -0.0358 | 0.017 | 0.0303 | 0.29 | -0.5 | -0.04 | 0.06 | -0.21 | -0.01 | 0.02 |
| Surprise Percentage | 10.5364% | 15.7895% | -20.5511% | 8.2126% | 15.9222% | 126.087% | -185.1852% | -28.5714% | 54.5455% | -700% | -5.2632% | 8.6957% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.2 |
| Currency | CHF |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ACIU
2026-04-16 16:38:47
AC Immune SA CEO Andrea Pfeifer completed an open-market sale of 10,000 company shares, as clarified in an amended Form 4/A. The initial filing mistakenly reported this as a purchase, which has now been corrected to a sale at a weighted average price of $3.1425 per share. Following this transaction, Pfeifer directly owns 3,830,288 shares and indirectly owns 14,000 shares through her spouse.
2026-04-16 15:38:47
AC Immune SA's CEO, Andrea Pfeifer, reported an open-market purchase of 10,000 common shares on April 15, 2026, at a weighted average price of $3.1425 per share. Following this transaction, her direct holdings increased to 3,830,288 shares, which include 1,921,005 shares underlying restricted share units, with an additional 14,000 shares indirectly owned through her spouse. This purchase reflects management's confidence in the company, with individual trade prices ranging from $3.05 to $3.19.
2026-04-16 13:38:47
The article reports that American Coastal Insurance Corporation (ACIU) stock rallied 16.3% over the past week. This performance follows recent gains over the last four weeks, reaching a 16.3% increase in just seven days. Investors will be interested in understanding the factors driving this significant price movement.
2026-04-15 21:09:50
Andrea Pfeifer, associated with AC Immune SA (NASDAQ: ACIU), has filed a Form 144 indicating her intent to sell 10,000 common shares valued at $31,900. The filing also details two previous 10b5-1 sales, each for 10,000 shares, occurring on March 16, 2026, and February 17, 2026. The shares to be sold originated from previously exercised stock options dated June 1, 2012, and Morgan Stanley Smith Barney LLC is identified as the broker for the proposed sale.
2026-04-15 07:40:27
AC Immune, a biopharmaceutical company based in Lausanne, has amended its agreement with Eli Lilly to further develop Tau Morphomer small molecule candidates for Alzheimer's disease and other neurodegenerative conditions. The expanded collaboration, which includes new lead candidates, will provide AC Immune with a CHF 10 million upfront payment and additional milestone payments, potentially reaching over CHF 1.7 billion. This initiative leverages AC Immune's Morphomer platform, which designs small molecules to target pathological forms of the Tau protein, a key driver in neurodegeneration.
2026-04-13 11:46:00
Leerink analyst Marc Goodman views AC Immune's amendment to their collaboration with Eli Lilly for the Morphomer Tau program as "great news." This amendment focuses on continued research into Tau aggregation inhibitor small molecules for early Alzheimer's prevention, suggesting Eli Lilly's sustained commitment despite previous challenges. AC Immune will receive an upfront payment and be eligible for significant milestones and royalties from this agreement.
